A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells.

Trial Profile

A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Irinotecan hyaluronic acid complex (Primary) ; Carboplatin; Irinotecan
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HA-Irinotecan small cell lung cancer trial
  • Most Recent Events

    • 13 Sep 2011 Recruitment into the phase II portion of the trial has been initiated.
    • 26 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top